FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasinington,	D.C.	20343	

Check this box if no longer subject to	STATEMENT OF CHANGES IN BENEFICIAL O	WNERSHIP
Section 16. Form 4 or Form 5		
- letter etter er er er er etter er er er		

OMB APPROVAL 3235-0287 Estimated average burden 0.5

hours per response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* MacDonald Glen C					2. Issuer Name and Ticker or Trading Symbol Sesen Bio, Inc. [SESN]								elationship o eck all applic Directo	able)	Perso	10% Ow	ner
(Last) (First) (Middle) C/O SESEN BIO, INC. SUITE 1800				0.	3. Date of Earliest Transaction (Month/Day/Year) 02/13/2020								X Officer (give title Other (specify below) Chief Technology Officer				
(Street)		1A	02142	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line	dividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(3	State)	(Zip)		6		- ^ -		D:		-f D-						
1. Title of Security (Instr. 3)		Transaction te onth/Day/	2A. Deemed Execution Date, if any (Month/Day/Year		3. Transac Code (I 8)	ction nstr. V	(0)		ed (A) or str. 3, 4 and	5. Amour Securitie Beneficia Owned Reported Transacti (Instr. 3 a	5. Amount of Securities Beneficially (I Owned Following Reported Transaction(s) (Instr. 3 and 4)		Direct I I Indirect Estr. 4)	7. Nature of indirect Beneficial Dwnership Instr. 4)			
			Table II - De (e.g					uired, D , option					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			of Securi Underlyir	g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported	es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisabl		xpiration ate	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Employee Stock Option (Right to Buy)	\$0.8911	02/13/2020		A		275,000		(1)	0	2/13/2030	Common Stock	275,000	\$0	275,00	0	D	

Explanation of Responses:

1. On February 13, 2020, the reporting person was awarded options to purchase 275,000 shares of the common stock of Sesen Bio, Inc. (the "Company"), which options vest 6.25% every three months over four years provided the reporting person is employed by the Company at each such vesting date.

Remarks:

/s/ Monica Forbes as attorney-

in-fact

** Signature of Reporting Person

Date

02/18/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.